Changes to This Summary (03/21/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about an open-label extension study of 43 patients that found that some patients continued to obtain relief of their cancer-related pain with long-term use of the delta-9-tetrahydrocannabinol:cannabidiol oromucosal spray without increasing their dose of the spray or the dose of their other analgesics (cited Johnson et al. as reference 38).
Added text about a randomized controlled trial of 39 patients with neuropathic pain who were treated with medium-dose, low-dose or placebo vaporized Cannabis that found that vaporized Cannabis produced comparable analgesic effects at both doses compared with placebo; psychoactive effects were minimal and well tolerated (cited Wilsey et al. as reference 42).
This summary is written and maintained by the PDQ Cancer Complementary and Alternative Medicine Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Back to Top